Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $7.00 price target on the stock.

ATOS has been the topic of a number of other research reports. Ascendiant Capital Markets upped their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Atossa Therapeutics Trading Down 2.6 %

Shares of NASDAQ:ATOS opened at $1.12 on Thursday. The stock has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.33. Atossa Therapeutics has a 12-month low of $0.70 and a 12-month high of $2.31. The stock has a market capitalization of $140.90 million, a price-to-earnings ratio of -5.09 and a beta of 1.21.

Institutional Investors Weigh In On Atossa Therapeutics

Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in shares of Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after acquiring an additional 399,041 shares during the period. Renaissance Technologies LLC grew its position in Atossa Therapeutics by 11.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after purchasing an additional 164,540 shares during the period. Rhumbline Advisers bought a new stake in Atossa Therapeutics in the 2nd quarter worth approximately $161,000. Barclays PLC raised its stake in Atossa Therapeutics by 280.9% during the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after buying an additional 123,683 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after buying an additional 78,269 shares during the period. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.